Abstract
Peripheral T-cell lymphomas (PTCL) represent about 12%-15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL.
Original language | English (US) |
---|---|
Pages (from-to) | 125-135 |
Number of pages | 11 |
Journal | Clinical Medicine Insights: Therapeutics |
Volume | 3 |
DOIs | |
State | Published - 2011 |
Keywords
- Pralatrexate
- Review
- T-cell lymphoma
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science